Clinical trial · Interventional
Study of DC-CIK to Treat NPC
A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Staging Ⅱ-Ⅲ of Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Concurrent of radiotherapy and chemotherapy is the main treatment method for patients with nasopharyngeal carcinoma (NPC). However, Relapse remains the major cause of treatment failure. A series of studies reported that dendritic and cytokine-induced killer cells (DC-CIK) have a broad anti-tumor spectrum. We suppose that DC-CIK will improve the prognosis of NPC. In this study, the patients with NPC will be treated with DC-CIK cells after concurrent of chemotherapy and radiotherapy. The purpose of this study is to evaluate the efficacy of DC-CIK for NPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC-CIK | Biological | — | UNRESOLVED |
| Dendritic and Cytokine-induced Killer Cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- B
- description
- After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
- type
- EXPERIMENTAL
- label
- A
- description
- After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
- interventionNames
- Biological: DC-CIK
- Biological: Dendritic and Cytokine-induced Killer Cells
Primary outcomes (1)
- measure
- progression-free survival(PFS)
- timeFrame
- 1 month
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with staging Ⅱ-Ⅲ of NPC; 2. Patients who had completed concurrent of radiotherapy and chemotherapy; 3. Patients who have a life expectancy of at least 12 weeks; 4. Eastern Cooperative Oncology Group (ECOG) performance status was 0-1; 5. The bone marrow functioned normally (WBC \> 4.0×109/L, Hb \> 120 g/L, PLT \> 100×109/L); 6. The ECG results were normal, and the liver and kidney were functional. Exclusion Criteria: 1. Patients who had distant metastases by imaging studies; 2. Patients with uncontrolled infection; underlying disease that was severe or life-threatening; 3. Patients who were pregnant or lactating; 4. ECOG perform status ≥ 2; 5. Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.
References
Publications (0)
Data not yet available